CYP2D6 polymorphisms and atypical antipsychotic weight gain.
Reports have linked atypical antipsychotics (AAPs) with weight gain. The polymorphic CYP2D6 involved in metabolism has been associated with medication morbidity. Eleven subjects receiving olanzapine were genotyped for CYP2D6 to examine the relationship between 2D6 and AAP weight gain. Using a linear regression, the dependent variable was percent change in body mass index (BMI). Genotype, dose and duration of treatment were independent. Genotype was significant (P<0.0097) for those with a *1/*3 or *4 genotype experiencing a larger percent BMI change than those with a *1/*1 genotype. This may be due to increased olanzapine concentrations leading to increased exposure, which may trigger AAP weight gain.
Ellingrod
Vicki L
VL
College of Pharmacy, University of Iowa, Iowa City, Iowa, USA. vicki-ellingrod@uiowa.edu
Miller
Del
D
Schultz
Susan K
SK
Wehring
Heidi
H
Arndt
Stephan
S
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*; D015430:Weight Gain / Q000187:drug effects / Q000235:genetics*
D014150:Antipsychotic Agents; D019389:Cytochrome P-450 CYP2D6